查看购物车
  • Traditional Chinese
  • English
  • Japanese
封面
市场调查报告书
商品编码
1863299

避孕药市场：2025-2032年全球预测（按剂型、包装、用药週期、价格分布、通路和最终用户划分）

Contraceptive Pills Market by Formulation, Packaging, Dosage Cycle, Pricing Tier, Distribution Channel, End User - Global Forecast 2025-2032
出版日期: | 出版商: 360iResearch | 英文 183 Pages | 商品交期: 最快1-2个工作天内

价格

※ 本网页内容可能与最新版本有所差异。详细情况请与我们联繫。

预计到 2032 年，避孕药具市场规模将达到 347.9 亿美元，年复合成长率为 6.66%。

关键市场统计数据
基准年 2024 207.6亿美元
预计年份：2025年 221.2亿美元
预测年份 2032 347.9亿美元
复合年增长率 (%) 6.66%

本文对影响避孕策略的临床创新、监管压力、供应链现状以及患者可及性的重要性进行了策略性介绍。

本执行摘要全面概述了影响避孕产品研发、分销和患者获取的当代趋势。这一趋势的特征是临床创新快速发展、法律规范不断加强、消费者偏好转向便利性和个人化，以及产品从生产商到最终用户的流通方式发生根本性变革。临床、商业和政策相关人员必须积极应对日益增长的对生殖健康政策和获取途径的关注，并在安全性、有效性、可负担性和供应稳定性之间取得平衡。

在过去的几个研发週期中，製剂科学的进步拓展了荷尔蒙谱和给药方案的选择范围，而数位管道和远端医疗则重新定义了诊疗点和药物支援。同时，在全球供应链面临地缘政治压力的背景下，製造商和经销商在品质和采购方面也面临日益严格的审查。本导言透过重点阐述临床差异化、法规遵循、供应链管理和消费者主导分销之间的交集，为后续章节建构了框架。其目的是帮助决策者为策略规划和营运调整建立清晰、基于证据的基础。

本文分析了临床、监管、数位化和供应方面的变革，这些变革正在重新定义避孕药价值的创造和交付方式。

避孕领域正经历多重变革，这些变革正在改变竞争格局和策略重点。临床创新透过优化荷尔蒙平衡和给药方案，优先考虑耐受性和週期灵活性，从而扩展产品的治疗益处和生活方式属性。同时，旨在提高依从性、提供远端处方协助以及将患者报告结果纳入上市后安全性监测的数位健康干预措施也蓬勃发展。这些因素共同作用，正在改变价值的定义，使其从单纯的疗效转向强调使用者体验、便利性和长期安全性证据的模式。

监管和政策趋势也是变革的关键驱动力。监管机构日益关注药品监管、产品可追溯性和供应链透明度，迫使製造商重新评估其采购和品质保证通讯协定。同时，支付方和医疗服务提供方的行为也在适应不同的成本控制和准入优先事项，重点在于确保不同族群都能公平地获得医疗服务。最后，供应链韧性正成为企业经营团队的焦点，各公司正寻求透过多元化供应来源、加强区域生产能力以及投资先进的库存管理来降低中断风险。这些累积性的变化正在创造一个重视敏捷性、基于证据的产品差异化以及严格监管合规的市场环境。

对 2025 年关税如何导致采购、製造和分销调整、重塑营运风险和供应商策略全面评估。

2025年关税的实施给避孕药具价值链带来了多方面的压力，促使製造商、经销商和采购团队采取战略应对措施。投入成本，特别是国际采购的活性药物成分和包装材料的成本，现在都需缴纳新的关税，改变了全球采购的模式。因此，製造商正在加快供应商多元化策略的实施，探索替代原材料来源，并在某些情况下考虑将生产基地设在更靠近市场的地方，以降低进口关税风险。这些调整波及采购计画、合约谈判和库存政策，改变了前置作业时间预期和供应商关係管理方式。

除了直接的成本影响外，关税还推动了营运和商业转型。企业正在加强与监管机构的合作，以加快对替代供应商的核准，并投资于品质保证，以促进新供应商合作伙伴的合格。分销网络也经过重新评估，优先考虑那些能够应对营运复杂性并维持服务水准的管道。支付者和批发商都在重新评估筹资策略，以平衡成本控制和供应可靠性，而药局也在调整其商品种类和库存管理方式。在此背景下，关税带来的变化如同结构性压力测试，加速了在地化进程，强化了供应链透明度的重要性，并促使整个生态系统重新评估合约设计和紧急时应对计画。

透过多维細項分析，将配方、包装、剂量、定价、分销和人口统计群体等因素与策略槓桿和产品定位联繫起来。

市场区隔提供了一个切实可行的观点，帮助我们了解在哪些方面，差异化的临床、包装、剂量、定价、分销和人口统计策略最有可能创造竞争优势。我们考虑了各种剂型的复方製剂和单孕激素片剂。在复方製剂中，我们进一步将产品设计细分为双相、单相、四相和三相给药方案，其中单相产品又细分为低剂量、标准剂量和超低剂量方案，以明确耐受性和副作用之间的权衡。这种製剂分类系统可以指南新参与企业和成熟品牌确定研发重点和临床定位。

目录

第一章：序言

第二章调查方法

第三章执行摘要

第四章 市场概览

第五章 市场洞察

  • 推广使用与避孕药疗程结合的数位不孕​​症追踪工具
  • 对含有新型胜肽类似物的非荷尔蒙避孕药的需求不断增长
  • 远距远端医疗处方服务推动避孕药邮寄配送市场成长
  • 研发一种能减少月经出血频率、减轻病人不便的长效避孕药
  • 选择性黄体素受体调变器口服避孕药的研究进展
  • 随着基于药物基因组学分析的个人化给药演算法的出现，优化疗效成为可能
  • 来自提供非处方避孕药的消费者保健品牌的竞争日益加剧
  • 透过将智慧型手机应用程式与用药提醒功能连接起来，减少健忘现象

第六章：美国关税的累积影响，2025年

第七章：人工智慧的累积影响，2025年

第八章 以剂型分類的避孕药市场

  • 复方药片
    • 双相
    • 单相
      • 低剂量
      • 标准剂量
      • 超低剂量
    • 四相
    • 三相
  • 仅含黄体素的片剂

9. 依包装分類的避孕药市场

  • 泡壳包装
  • 条状包装

第十章 以剂量週期分類的避孕药市场

  • 21天疗程
  • 28天疗程
  • 延长週期

第十一章 依价格分布的避孕药市场

  • 品牌产品
  • 学名药

第十二章 按分销管道分類的避孕药市场

  • 诊所药房
  • 医院药房
  • 网路药房
  • 零售药房
    • 连锁药局
    • 独立药房

第十三章 依最终用户分類的避孕药市场

  • 青春期
  • 成人
    • 20-24岁
    • 25-29岁
    • 30-34岁
  • 成熟的成年人

第十四章 各地区避孕药市场

  • 美洲
    • 北美洲
    • 拉丁美洲
  • 欧洲、中东和非洲
    • 欧洲
    • 中东
    • 非洲
  • 亚太地区

第十五章 按群体分類的避孕药市场

  • ASEAN
  • GCC
  • EU
  • BRICS
  • G7
  • NATO

第十六章 各国避孕药具市场

  • 美国
  • 加拿大
  • 墨西哥
  • 巴西
  • 英国
  • 德国
  • 法国
  • 俄罗斯
  • 义大利
  • 西班牙
  • 中国
  • 印度
  • 日本
  • 澳洲
  • 韩国

第十七章 竞争格局

  • 2024年市占率分析
  • FPNV定位矩阵，2024
  • 竞争分析
    • Bayer AG
    • Pfizer Inc.
    • Organon & Co.
    • Johnson & Johnson
    • Teva Pharmaceutical Industries Ltd.
    • Viatris Inc.
    • Novartis AG
    • Aurobindo Pharma Limited
    • Sun Pharmaceutical Industries Limited
    • Cipla Limited
Product Code: MRR-A579C4315A23

The Contraceptive Pills Market is projected to grow by USD 34.79 billion at a CAGR of 6.66% by 2032.

KEY MARKET STATISTICS
Base Year [2024] USD 20.76 billion
Estimated Year [2025] USD 22.12 billion
Forecast Year [2032] USD 34.79 billion
CAGR (%) 6.66%

A strategic introduction that frames clinical innovation, regulatory pressures, supply-chain realities, and patient access imperatives shaping contraceptive pill strategy

This executive summary introduces a comprehensive synthesis of contemporary dynamics shaping contraceptive pill development, distribution, and patient access. The landscape is defined by rapid clinical innovation, evolving regulatory oversight, shifting consumer preferences toward convenience and personalization, and material changes in how products move from manufacturer to end user. Stakeholders across clinical, commercial, and policy domains must balance safety, efficacy, affordability, and supply resilience while responding to heightened attention on reproductive health policy and access.

Over the past several cycles, progress in formulation science has expanded options across hormonal profiles and dosing regimens, while digital channels and telehealth have redefined points of care and adherence support. Concurrently, manufacturers and distributors face intensified scrutiny on quality and sourcing as global supply chains confront geopolitical pressures. This introduction frames the subsequent sections by highlighting the intersection of clinical differentiation, regulatory compliance, supply-chain management, and consumer-directed distribution. The intent is to equip decision-makers with a clear, evidence-informed foundation for strategic planning and operational adaptation.

An analysis of clinical, regulatory, digital, and supply-side shifts that are redefining how contraceptive pill value is created and delivered to users

The contraceptive pill sector is undergoing several transformative shifts that are altering competitive positioning and strategic priorities. Clinical innovation is broadening the therapeutic and lifestyle attributes of products through refined hormonal balances and dosing regimens that prioritize tolerability and cycle flexibility. These clinical developments are complemented by a surge in digital health interventions aimed at improving adherence, facilitating remote prescribing, and integrating patient-reported outcomes into post-market safety surveillance. Together, these forces are reshaping how value is defined beyond efficacy alone, moving toward a model that prizes user experience, convenience, and longitudinal safety evidence.

Regulatory and policy dynamics also constitute a significant axis of change. Authorities are increasingly focused on pharmacovigilance, product traceability, and supply-chain transparency, which has prompted manufacturers to re-evaluate sourcing and quality assurance protocols. At the same time, payer and provider behaviors are adapting to different cost-containment and access priorities, with an emphasis on ensuring equitable access across diverse demographic segments. Finally, supply-chain resilience has become a board-level concern; firms are investing in diversified suppliers, regional manufacturing capacity, and advanced inventory management to mitigate disruption. The cumulative effect of these shifts is a market environment that rewards agility, evidence-driven product differentiation, and tightly managed regulatory compliance.

A comprehensive assessment of how tariff actions in 2025 triggered procurement, manufacturing, and distribution adaptations reshaping operational risk and supplier strategies

The introduction of tariffs in 2025 has exerted multi-dimensional pressure across the contraceptive pill value chain, prompting strategic responses from manufacturers, distributors, and procurement teams. Input costs for active pharmaceutical ingredients and packaging materials, particularly those sourced internationally, have been subjected to new duties that changed the calculus of global procurement. As a result, manufacturers have accelerated supplier diversification strategies, sought alternative raw-material sources, and in some cases considered closer-to-market production footprints to mitigate exposure to import levies. These adjustments have flowed through procurement plans, contractual negotiations, and inventory policies, altering lead-time assumptions and supplier relationship management.

Beyond direct cost implications, tariffs have catalyzed operational and commercial shifts. Firms have increased engagement with regulatory authorities to expedite approvals for alternative suppliers and have invested in quality assurance to facilitate qualification of new supply partners. Distribution networks have been reassessed to prioritize channels that can absorb operational complexity while preserving service levels. Payers and wholesalers are likewise recalibrating procurement strategies to balance cost containment with supply reliability, and pharmacies are adapting their assortment and stocking practices. In this context, tariff-induced change functions as a structural stress test that accelerates localization, elevates the importance of supply-chain transparency, and compels a reappraisal of contract design and contingency planning across the ecosystem.

A multidimensional segmentation analysis mapping formulation, packaging, dosing, pricing, distribution, and demographic cohorts to strategic levers and product positioning

Segmentation provides a practical lens to understand where differentiated clinical, packaging, dosing, pricing, distribution, and demographic strategies are most likely to yield competitive advantage. Based on formulation, the landscape is examined across combination pill and progestin-only pill options. Within combination therapies, product design is further stratified into biphasic, monophasic, quadriphasic, and triphasic regimens, and monophasic offerings are assessed at low dose, standard dose, and ultra-low dose gradations to clarify tolerability and side-effect trade-offs. This formulation taxonomy informs development priorities and clinical positioning for both newer entrants and legacy brands.

Based on packaging, products are categorized across blister pack and strip pack formats, where packaging choices influence adherence support, dispensing preferences, and waste management considerations. Based on dosage cycle, regimens include 21-day, 28-day, and extended-cycle options, each aligning to different user lifestyle preferences and clinical guidance. Based on pricing tier, the competitive dynamic spans branded and generic offerings, which intersect with payer contracting and formulary placement strategies. Based on distribution channel, the ecosystem includes clinic pharmacy, hospital pharmacy, online pharmacy, and retail pharmacy, with retail pharmacy further subdivided into chain pharmacy and independent pharmacy, a distinction that affects stocking decisions and promotional approaches. Based on end user, segmentation addresses adolescents, adults, and mature adults, with adults further detailed across 20-24, 25-29, and 30-34 cohorts to capture life-stage needs, fertility planning behaviors, and adherence drivers. Together, these segmentation lenses enable prioritization of product development, channel alignment, and messaging frameworks tailored to distinct clinical and commercial use cases.

Regionally calibrated intelligence that links regulatory regimes, distribution structures, and patient behaviors across the Americas, Europe, Middle East & Africa, and Asia-Pacific

Regional dynamics shape product strategy through regulatory environments, public health priorities, distribution infrastructure, and consumer behavior. In the Americas, policy debates and access initiatives coexist with mature retail and digital pharmacy channels; this region emphasizes reproductive health access programs, clinician-prescribing practices, and payer negotiations that influence formulary positioning and distribution partnerships. Manufacturers operating here prioritize compliance with stringent pharmacovigilance standards and leverage digital adherence tools and telehealth integrations to support patient retention and clinician engagement.

In Europe, Middle East & Africa, heterogeneity is pronounced; regulatory regimes vary from highly centralized approval pathways to fragmented national systems, and distribution infrastructures range from robust hospital and retail networks to emerging online pharmacy ecosystems. This region requires nuanced market-entry strategies that balance centralized clinical evidence generation with localized regulatory and reimbursement tactics. The Asia-Pacific region presents a combination of rapid digital adoption and growing domestic manufacturing capability, where demand patterns are shaped by demographic trends, urbanization, and expanding pharmacy e-commerce. Across all regions, stakeholders are responding to supply-chain considerations and local policy shifts while innovating in packaging and service delivery models to meet distinct regional needs.

An executive synthesis of corporate strategies emphasizing formulation innovation, supply resilience, omnichannel distribution, and evidence-based differentiation

Leading companies in the contraceptive pill arena are pursuing differentiated strategies that span clinical innovation, portfolio rationalization, and vertical integration. Several manufacturers are investing in formulation upgrades to improve tolerability and adherence, while others are prioritizing cost-competitive generics to secure distribution agreements with large pharmacy chains and institutional buyers. Strategic partnerships with contract manufacturers and specialty packaging firms are increasingly common as firms seek to de-risk production and accelerate time-to-shelf for reformulated assets.

Commercially, organizations are experimenting with omnichannel distribution models that combine clinic-based initiation, online follow-up, and subscription-based fulfillment to enhance retention. Similarly, companies are strengthening pharmacovigilance capabilities and real-world evidence programs to support regulatory submissions and payer discussions. On the supply side, firms with flexible manufacturing footprints and robust supplier qualification programs have improved operational resilience, enabling them to respond more quickly to procurement disruptions and to qualify alternative APIs and packaging sources. Collectively, these corporate moves underscore a broader industry emphasis on agility, integrated data capabilities, and patient-centric service models.

Practical strategic and operational recommendations for executives to enhance product differentiation, supply resilience, digital distribution, and payer engagement across portfolios

Prioritize formulation and product development initiatives that align clinical differentiation with user-centric benefits; invest in tolerability profiles and extended-cycle options that respond to clinician guidance and patient lifestyle preferences. Simultaneously, codify supplier diversification strategies and establish alternative qualified sources for critical inputs to reduce tariff exposure and shipment delays. Strengthen supplier qualification and quality assurance processes so that new sourcing arrangements do not compromise regulatory compliance or patient safety.

Elevate digital and distribution capabilities by integrating telehealth-friendly prescribing workflows and subscription fulfillment models that improve adherence and retention. Engage proactively with payers and health systems to demonstrate value through real-world safety and adherence data rather than relying solely on traditional clinical endpoints. Finally, design commercial models that account for regional regulatory variance and channel nuances, tailoring packaging and pricing approaches to local distribution structures while preserving the ability to scale successful programs across adjacent markets.

A transparent description of the integrated primary and secondary research approach, validation processes, and quality controls underpinning the analysis

The research underpinning this report integrates primary qualitative inquiry with a systematic secondary evidence synthesis to deliver balanced, actionable insights. Primary engagement includes structured interviews with clinicians, pharmacists, procurement specialists, manufacturing leaders, and regulatory experts to capture operational realities and emergent clinical preferences. These conversations are designed to surface practical challenges in sourcing, prescribing, and distribution as well as perspectives on patient adherence and safety monitoring.

Secondary research involved comprehensive review of peer-reviewed clinical literature, regulatory guidance documents, patent and approval records, industry technical bulletins, and publicly available corporate disclosures to validate thematic findings and ensure alignment with current standards of care and regulatory expectations. Data triangulation and cross-validation were applied throughout to reconcile conflicting viewpoints and to highlight areas where evidence is robust versus where uncertainty remains. Quality controls included methodological audits, expert review panels, and iterative validation with select interviewees to ensure fidelity to real-world practice and operational constraints.

A concise concluding synthesis emphasizing integrated strategies that combine clinical innovation, supply resilience, and distribution agility for long-term leadership

The contraceptive pill landscape is at an inflection point where clinical refinement, regulatory rigor, supply-chain resilience, and evolving distribution models intersect. Progress in formulation science and dosing flexibility expands clinical options and enhances user-centered outcomes, while digital health and telemedicine pathways are creating new access routes and adherence support mechanisms. At the same time, geopolitical and trade developments have highlighted vulnerabilities in global sourcing, catalyzing a strategic shift toward supplier diversification and regional manufacturing considerations.

For senior leaders, the imperative is to adopt an integrated approach that aligns product innovation with operational resilience and channel-first commercial models. Organizations that combine rigorous quality systems, adaptable supply chains, and evidence-driven commercialization will be best positioned to respond to policy shifts, competitive pressures, and changing patient expectations. Strategic investments made today in formulation, data infrastructure, and distribution orchestration will determine which firms lead the next phase of value creation in contraceptive care.

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Segmentation & Coverage
  • 1.3. Years Considered for the Study
  • 1.4. Currency & Pricing
  • 1.5. Language
  • 1.6. Stakeholders

2. Research Methodology

3. Executive Summary

4. Market Overview

5. Market Insights

  • 5.1. Increasing adoption of digital fertility tracking integrations with contraceptive pill regimens
  • 5.2. Rising demand for non-hormonal contraceptive pills formulated with novel peptide analogs
  • 5.3. Market growth driven by telehealth prescription services for mail delivery of contraceptives
  • 5.4. Development of extended cycle pills reducing menstrual bleeding frequency and patient inconvenience
  • 5.5. Research advancements in selective progesterone receptor modulator oral contraceptives
  • 5.6. Emergence of personalized dosing algorithms based on pharmacogenomic profiling to optimize efficacy
  • 5.7. Increasing competition from consumer health brands offering over-the-counter contraceptive pill options
  • 5.8. Integration of smartphone apps with pill adherence reminders to reduce missed dosage rates

6. Cumulative Impact of United States Tariffs 2025

7. Cumulative Impact of Artificial Intelligence 2025

8. Contraceptive Pills Market, by Formulation

  • 8.1. Combination Pill
    • 8.1.1. Biphasic
    • 8.1.2. Monophasic
      • 8.1.2.1. Low Dose
      • 8.1.2.2. Standard Dose
      • 8.1.2.3. Ultra-Low Dose
    • 8.1.3. Quadriphasic
    • 8.1.4. Triphasic
  • 8.2. Progestin-Only Pill

9. Contraceptive Pills Market, by Packaging

  • 9.1. Blister Pack
  • 9.2. Strip Pack

10. Contraceptive Pills Market, by Dosage Cycle

  • 10.1. 21-Day Regimen
  • 10.2. 28-Day Regimen
  • 10.3. Extended Cycle

11. Contraceptive Pills Market, by Pricing Tier

  • 11.1. Branded
  • 11.2. Generic

12. Contraceptive Pills Market, by Distribution Channel

  • 12.1. Clinic Pharmacy
  • 12.2. Hospital Pharmacy
  • 12.3. Online Pharmacy
  • 12.4. Retail Pharmacy
    • 12.4.1. Chain Pharmacy
    • 12.4.2. Independent Pharmacy

13. Contraceptive Pills Market, by End User

  • 13.1. Adolescents
  • 13.2. Adults
    • 13.2.1. 20-24
    • 13.2.2. 25-29
    • 13.2.3. 30-34
  • 13.3. Mature Adults

14. Contraceptive Pills Market, by Region

  • 14.1. Americas
    • 14.1.1. North America
    • 14.1.2. Latin America
  • 14.2. Europe, Middle East & Africa
    • 14.2.1. Europe
    • 14.2.2. Middle East
    • 14.2.3. Africa
  • 14.3. Asia-Pacific

15. Contraceptive Pills Market, by Group

  • 15.1. ASEAN
  • 15.2. GCC
  • 15.3. European Union
  • 15.4. BRICS
  • 15.5. G7
  • 15.6. NATO

16. Contraceptive Pills Market, by Country

  • 16.1. United States
  • 16.2. Canada
  • 16.3. Mexico
  • 16.4. Brazil
  • 16.5. United Kingdom
  • 16.6. Germany
  • 16.7. France
  • 16.8. Russia
  • 16.9. Italy
  • 16.10. Spain
  • 16.11. China
  • 16.12. India
  • 16.13. Japan
  • 16.14. Australia
  • 16.15. South Korea

17. Competitive Landscape

  • 17.1. Market Share Analysis, 2024
  • 17.2. FPNV Positioning Matrix, 2024
  • 17.3. Competitive Analysis
    • 17.3.1. Bayer AG
    • 17.3.2. Pfizer Inc.
    • 17.3.3. Organon & Co.
    • 17.3.4. Johnson & Johnson
    • 17.3.5. Teva Pharmaceutical Industries Ltd.
    • 17.3.6. Viatris Inc.
    • 17.3.7. Novartis AG
    • 17.3.8. Aurobindo Pharma Limited
    • 17.3.9. Sun Pharmaceutical Industries Limited
    • 17.3.10. Cipla Limited

LIST OF FIGURES

  • FIGURE 1. GLOBAL CONTRACEPTIVE PILLS MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 2. GLOBAL CONTRACEPTIVE PILLS MARKET SIZE, BY FORMULATION, 2024 VS 2032 (%)
  • FIGURE 3. GLOBAL CONTRACEPTIVE PILLS MARKET SIZE, BY FORMULATION, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 4. GLOBAL CONTRACEPTIVE PILLS MARKET SIZE, BY PACKAGING, 2024 VS 2032 (%)
  • FIGURE 5. GLOBAL CONTRACEPTIVE PILLS MARKET SIZE, BY PACKAGING, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 6. GLOBAL CONTRACEPTIVE PILLS MARKET SIZE, BY DOSAGE CYCLE, 2024 VS 2032 (%)
  • FIGURE 7. GLOBAL CONTRACEPTIVE PILLS MARKET SIZE, BY DOSAGE CYCLE, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 8. GLOBAL CONTRACEPTIVE PILLS MARKET SIZE, BY PRICING TIER, 2024 VS 2032 (%)
  • FIGURE 9. GLOBAL CONTRACEPTIVE PILLS MARKET SIZE, BY PRICING TIER, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 10. GLOBAL CONTRACEPTIVE PILLS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024 VS 2032 (%)
  • FIGURE 11. GLOBAL CONTRACEPTIVE PILLS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 12. GLOBAL CONTRACEPTIVE PILLS MARKET SIZE, BY END USER, 2024 VS 2032 (%)
  • FIGURE 13. GLOBAL CONTRACEPTIVE PILLS MARKET SIZE, BY END USER, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 14. GLOBAL CONTRACEPTIVE PILLS MARKET SIZE, BY REGION, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 15. AMERICAS CONTRACEPTIVE PILLS MARKET SIZE, BY SUBREGION, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 16. NORTH AMERICA CONTRACEPTIVE PILLS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 17. LATIN AMERICA CONTRACEPTIVE PILLS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 18. EUROPE, MIDDLE EAST & AFRICA CONTRACEPTIVE PILLS MARKET SIZE, BY SUBREGION, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 19. EUROPE CONTRACEPTIVE PILLS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 20. MIDDLE EAST CONTRACEPTIVE PILLS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 21. AFRICA CONTRACEPTIVE PILLS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 22. ASIA-PACIFIC CONTRACEPTIVE PILLS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 23. GLOBAL CONTRACEPTIVE PILLS MARKET SIZE, BY GROUP, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 24. ASEAN CONTRACEPTIVE PILLS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 25. GCC CONTRACEPTIVE PILLS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 26. EUROPEAN UNION CONTRACEPTIVE PILLS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 27. BRICS CONTRACEPTIVE PILLS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 28. G7 CONTRACEPTIVE PILLS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 29. NATO CONTRACEPTIVE PILLS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 30. GLOBAL CONTRACEPTIVE PILLS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 31. CONTRACEPTIVE PILLS MARKET SHARE, BY KEY PLAYER, 2024
  • FIGURE 32. CONTRACEPTIVE PILLS MARKET, FPNV POSITIONING MATRIX, 2024

LIST OF TABLES

  • TABLE 1. CONTRACEPTIVE PILLS MARKET SEGMENTATION & COVERAGE
  • TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2024
  • TABLE 3. GLOBAL CONTRACEPTIVE PILLS MARKET SIZE, 2018-2024 (USD MILLION)
  • TABLE 4. GLOBAL CONTRACEPTIVE PILLS MARKET SIZE, 2025-2032 (USD MILLION)
  • TABLE 5. GLOBAL CONTRACEPTIVE PILLS MARKET SIZE, BY FORMULATION, 2018-2024 (USD MILLION)
  • TABLE 6. GLOBAL CONTRACEPTIVE PILLS MARKET SIZE, BY FORMULATION, 2025-2032 (USD MILLION)
  • TABLE 7. GLOBAL CONTRACEPTIVE PILLS MARKET SIZE, BY COMBINATION PILL, 2018-2024 (USD MILLION)
  • TABLE 8. GLOBAL CONTRACEPTIVE PILLS MARKET SIZE, BY COMBINATION PILL, 2025-2032 (USD MILLION)
  • TABLE 9. GLOBAL CONTRACEPTIVE PILLS MARKET SIZE, BY COMBINATION PILL, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 10. GLOBAL CONTRACEPTIVE PILLS MARKET SIZE, BY COMBINATION PILL, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 11. GLOBAL CONTRACEPTIVE PILLS MARKET SIZE, BY COMBINATION PILL, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 12. GLOBAL CONTRACEPTIVE PILLS MARKET SIZE, BY COMBINATION PILL, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 13. GLOBAL CONTRACEPTIVE PILLS MARKET SIZE, BY COMBINATION PILL, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 14. GLOBAL CONTRACEPTIVE PILLS MARKET SIZE, BY COMBINATION PILL, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 15. GLOBAL CONTRACEPTIVE PILLS MARKET SIZE, BY BIPHASIC, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 16. GLOBAL CONTRACEPTIVE PILLS MARKET SIZE, BY BIPHASIC, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 17. GLOBAL CONTRACEPTIVE PILLS MARKET SIZE, BY BIPHASIC, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 18. GLOBAL CONTRACEPTIVE PILLS MARKET SIZE, BY BIPHASIC, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 19. GLOBAL CONTRACEPTIVE PILLS MARKET SIZE, BY BIPHASIC, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 20. GLOBAL CONTRACEPTIVE PILLS MARKET SIZE, BY BIPHASIC, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 21. GLOBAL CONTRACEPTIVE PILLS MARKET SIZE, BY MONOPHASIC, 2018-2024 (USD MILLION)
  • TABLE 22. GLOBAL CONTRACEPTIVE PILLS MARKET SIZE, BY MONOPHASIC, 2025-2032 (USD MILLION)
  • TABLE 23. GLOBAL CONTRACEPTIVE PILLS MARKET SIZE, BY MONOPHASIC, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 24. GLOBAL CONTRACEPTIVE PILLS MARKET SIZE, BY MONOPHASIC, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 25. GLOBAL CONTRACEPTIVE PILLS MARKET SIZE, BY MONOPHASIC, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 26. GLOBAL CONTRACEPTIVE PILLS MARKET SIZE, BY MONOPHASIC, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 27. GLOBAL CONTRACEPTIVE PILLS MARKET SIZE, BY MONOPHASIC, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 28. GLOBAL CONTRACEPTIVE PILLS MARKET SIZE, BY MONOPHASIC, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 29. GLOBAL CONTRACEPTIVE PILLS MARKET SIZE, BY LOW DOSE, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 30. GLOBAL CONTRACEPTIVE PILLS MARKET SIZE, BY LOW DOSE, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 31. GLOBAL CONTRACEPTIVE PILLS MARKET SIZE, BY LOW DOSE, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 32. GLOBAL CONTRACEPTIVE PILLS MARKET SIZE, BY LOW DOSE, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 33. GLOBAL CONTRACEPTIVE PILLS MARKET SIZE, BY LOW DOSE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 34. GLOBAL CONTRACEPTIVE PILLS MARKET SIZE, BY LOW DOSE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 35. GLOBAL CONTRACEPTIVE PILLS MARKET SIZE, BY STANDARD DOSE, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 36. GLOBAL CONTRACEPTIVE PILLS MARKET SIZE, BY STANDARD DOSE, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 37. GLOBAL CONTRACEPTIVE PILLS MARKET SIZE, BY STANDARD DOSE, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 38. GLOBAL CONTRACEPTIVE PILLS MARKET SIZE, BY STANDARD DOSE, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 39. GLOBAL CONTRACEPTIVE PILLS MARKET SIZE, BY STANDARD DOSE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 40. GLOBAL CONTRACEPTIVE PILLS MARKET SIZE, BY STANDARD DOSE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 41. GLOBAL CONTRACEPTIVE PILLS MARKET SIZE, BY ULTRA-LOW DOSE, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 42. GLOBAL CONTRACEPTIVE PILLS MARKET SIZE, BY ULTRA-LOW DOSE, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 43. GLOBAL CONTRACEPTIVE PILLS MARKET SIZE, BY ULTRA-LOW DOSE, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 44. GLOBAL CONTRACEPTIVE PILLS MARKET SIZE, BY ULTRA-LOW DOSE, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 45. GLOBAL CONTRACEPTIVE PILLS MARKET SIZE, BY ULTRA-LOW DOSE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 46. GLOBAL CONTRACEPTIVE PILLS MARKET SIZE, BY ULTRA-LOW DOSE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 47. GLOBAL CONTRACEPTIVE PILLS MARKET SIZE, BY QUADRIPHASIC, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 48. GLOBAL CONTRACEPTIVE PILLS MARKET SIZE, BY QUADRIPHASIC, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 49. GLOBAL CONTRACEPTIVE PILLS MARKET SIZE, BY QUADRIPHASIC, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 50. GLOBAL CONTRACEPTIVE PILLS MARKET SIZE, BY QUADRIPHASIC, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 51. GLOBAL CONTRACEPTIVE PILLS MARKET SIZE, BY QUADRIPHASIC, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 52. GLOBAL CONTRACEPTIVE PILLS MARKET SIZE, BY QUADRIPHASIC, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 53. GLOBAL CONTRACEPTIVE PILLS MARKET SIZE, BY TRIPHASIC, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 54. GLOBAL CONTRACEPTIVE PILLS MARKET SIZE, BY TRIPHASIC, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 55. GLOBAL CONTRACEPTIVE PILLS MARKET SIZE, BY TRIPHASIC, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 56. GLOBAL CONTRACEPTIVE PILLS MARKET SIZE, BY TRIPHASIC, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 57. GLOBAL CONTRACEPTIVE PILLS MARKET SIZE, BY TRIPHASIC, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 58. GLOBAL CONTRACEPTIVE PILLS MARKET SIZE, BY TRIPHASIC, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 59. GLOBAL CONTRACEPTIVE PILLS MARKET SIZE, BY PROGESTIN-ONLY PILL, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 60. GLOBAL CONTRACEPTIVE PILLS MARKET SIZE, BY PROGESTIN-ONLY PILL, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 61. GLOBAL CONTRACEPTIVE PILLS MARKET SIZE, BY PROGESTIN-ONLY PILL, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 62. GLOBAL CONTRACEPTIVE PILLS MARKET SIZE, BY PROGESTIN-ONLY PILL, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 63. GLOBAL CONTRACEPTIVE PILLS MARKET SIZE, BY PROGESTIN-ONLY PILL, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 64. GLOBAL CONTRACEPTIVE PILLS MARKET SIZE, BY PROGESTIN-ONLY PILL, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 65. GLOBAL CONTRACEPTIVE PILLS MARKET SIZE, BY PACKAGING, 2018-2024 (USD MILLION)
  • TABLE 66. GLOBAL CONTRACEPTIVE PILLS MARKET SIZE, BY PACKAGING, 2025-2032 (USD MILLION)
  • TABLE 67. GLOBAL CONTRACEPTIVE PILLS MARKET SIZE, BY BLISTER PACK, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 68. GLOBAL CONTRACEPTIVE PILLS MARKET SIZE, BY BLISTER PACK, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 69. GLOBAL CONTRACEPTIVE PILLS MARKET SIZE, BY BLISTER PACK, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 70. GLOBAL CONTRACEPTIVE PILLS MARKET SIZE, BY BLISTER PACK, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 71. GLOBAL CONTRACEPTIVE PILLS MARKET SIZE, BY BLISTER PACK, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 72. GLOBAL CONTRACEPTIVE PILLS MARKET SIZE, BY BLISTER PACK, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 73. GLOBAL CONTRACEPTIVE PILLS MARKET SIZE, BY STRIP PACK, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 74. GLOBAL CONTRACEPTIVE PILLS MARKET SIZE, BY STRIP PACK, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 75. GLOBAL CONTRACEPTIVE PILLS MARKET SIZE, BY STRIP PACK, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 76. GLOBAL CONTRACEPTIVE PILLS MARKET SIZE, BY STRIP PACK, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 77. GLOBAL CONTRACEPTIVE PILLS MARKET SIZE, BY STRIP PACK, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 78. GLOBAL CONTRACEPTIVE PILLS MARKET SIZE, BY STRIP PACK, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 79. GLOBAL CONTRACEPTIVE PILLS MARKET SIZE, BY DOSAGE CYCLE, 2018-2024 (USD MILLION)
  • TABLE 80. GLOBAL CONTRACEPTIVE PILLS MARKET SIZE, BY DOSAGE CYCLE, 2025-2032 (USD MILLION)
  • TABLE 81. GLOBAL CONTRACEPTIVE PILLS MARKET SIZE, BY 21-DAY REGIMEN, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 82. GLOBAL CONTRACEPTIVE PILLS MARKET SIZE, BY 21-DAY REGIMEN, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 83. GLOBAL CONTRACEPTIVE PILLS MARKET SIZE, BY 21-DAY REGIMEN, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 84. GLOBAL CONTRACEPTIVE PILLS MARKET SIZE, BY 21-DAY REGIMEN, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 85. GLOBAL CONTRACEPTIVE PILLS MARKET SIZE, BY 21-DAY REGIMEN, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 86. GLOBAL CONTRACEPTIVE PILLS MARKET SIZE, BY 21-DAY REGIMEN, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 87. GLOBAL CONTRACEPTIVE PILLS MARKET SIZE, BY 28-DAY REGIMEN, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 88. GLOBAL CONTRACEPTIVE PILLS MARKET SIZE, BY 28-DAY REGIMEN, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 89. GLOBAL CONTRACEPTIVE PILLS MARKET SIZE, BY 28-DAY REGIMEN, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 90. GLOBAL CONTRACEPTIVE PILLS MARKET SIZE, BY 28-DAY REGIMEN, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 91. GLOBAL CONTRACEPTIVE PILLS MARKET SIZE, BY 28-DAY REGIMEN, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 92. GLOBAL CONTRACEPTIVE PILLS MARKET SIZE, BY 28-DAY REGIMEN, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 93. GLOBAL CONTRACEPTIVE PILLS MARKET SIZE, BY EXTENDED CYCLE, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 94. GLOBAL CONTRACEPTIVE PILLS MARKET SIZE, BY EXTENDED CYCLE, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 95. GLOBAL CONTRACEPTIVE PILLS MARKET SIZE, BY EXTENDED CYCLE, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 96. GLOBAL CONTRACEPTIVE PILLS MARKET SIZE, BY EXTENDED CYCLE, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 97. GLOBAL CONTRACEPTIVE PILLS MARKET SIZE, BY EXTENDED CYCLE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 98. GLOBAL CONTRACEPTIVE PILLS MARKET SIZE, BY EXTENDED CYCLE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 99. GLOBAL CONTRACEPTIVE PILLS MARKET SIZE, BY PRICING TIER, 2018-2024 (USD MILLION)
  • TABLE 100. GLOBAL CONTRACEPTIVE PILLS MARKET SIZE, BY PRICING TIER, 2025-2032 (USD MILLION)
  • TABLE 101. GLOBAL CONTRACEPTIVE PILLS MARKET SIZE, BY BRANDED, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 102. GLOBAL CONTRACEPTIVE PILLS MARKET SIZE, BY BRANDED, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 103. GLOBAL CONTRACEPTIVE PILLS MARKET SIZE, BY BRANDED, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 104. GLOBAL CONTRACEPTIVE PILLS MARKET SIZE, BY BRANDED, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 105. GLOBAL CONTRACEPTIVE PILLS MARKET SIZE, BY BRANDED, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 106. GLOBAL CONTRACEPTIVE PILLS MARKET SIZE, BY BRANDED, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 107. GLOBAL CONTRACEPTIVE PILLS MARKET SIZE, BY GENERIC, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 108. GLOBAL CONTRACEPTIVE PILLS MARKET SIZE, BY GENERIC, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 109. GLOBAL CONTRACEPTIVE PILLS MARKET SIZE, BY GENERIC, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 110. GLOBAL CONTRACEPTIVE PILLS MARKET SIZE, BY GENERIC, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 111. GLOBAL CONTRACEPTIVE PILLS MARKET SIZE, BY GENERIC, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 112. GLOBAL CONTRACEPTIVE PILLS MARKET SIZE, BY GENERIC, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 113. GLOBAL CONTRACEPTIVE PILLS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
  • TABLE 114. GLOBAL CONTRACEPTIVE PILLS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2032 (USD MILLION)
  • TABLE 115. GLOBAL CONTRACEPTIVE PILLS MARKET SIZE, BY CLINIC PHARMACY, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 116. GLOBAL CONTRACEPTIVE PILLS MARKET SIZE, BY CLINIC PHARMACY, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 117. GLOBAL CONTRACEPTIVE PILLS MARKET SIZE, BY CLINIC PHARMACY, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 118. GLOBAL CONTRACEPTIVE PILLS MARKET SIZE, BY CLINIC PHARMACY, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 119. GLOBAL CONTRACEPTIVE PILLS MARKET SIZE, BY CLINIC PHARMACY, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 120. GLOBAL CONTRACEPTIVE PILLS MARKET SIZE, BY CLINIC PHARMACY, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 121. GLOBAL CONTRACEPTIVE PILLS MARKET SIZE, BY HOSPITAL PHARMACY, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 122. GLOBAL CONTRACEPTIVE PILLS MARKET SIZE, BY HOSPITAL PHARMACY, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 123. GLOBAL CONTRACEPTIVE PILLS MARKET SIZE, BY HOSPITAL PHARMACY, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 124. GLOBAL CONTRACEPTIVE PILLS MARKET SIZE, BY HOSPITAL PHARMACY, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 125. GLOBAL CONTRACEPTIVE PILLS MARKET SIZE, BY HOSPITAL PHARMACY, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 126. GLOBAL CONTRACEPTIVE PILLS MARKET SIZE, BY HOSPITAL PHARMACY, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 127. GLOBAL CONTRACEPTIVE PILLS MARKET SIZE, BY ONLINE PHARMACY, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 128. GLOBAL CONTRACEPTIVE PILLS MARKET SIZE, BY ONLINE PHARMACY, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 129. GLOBAL CONTRACEPTIVE PILLS MARKET SIZE, BY ONLINE PHARMACY, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 130. GLOBAL CONTRACEPTIVE PILLS MARKET SIZE, BY ONLINE PHARMACY, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 131. GLOBAL CONTRACEPTIVE PILLS MARKET SIZE, BY ONLINE PHARMACY, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 132. GLOBAL CONTRACEPTIVE PILLS MARKET SIZE, BY ONLINE PHARMACY, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 133. GLOBAL CONTRACEPTIVE PILLS MARKET SIZE, BY RETAIL PHARMACY, 2018-2024 (USD MILLION)
  • TABLE 134. GLOBAL CONTRACEPTIVE PILLS MARKET SIZE, BY RETAIL PHARMACY, 2025-2032 (USD MILLION)
  • TABLE 135. GLOBAL CONTRACEPTIVE PILLS MARKET SIZE, BY RETAIL PHARMACY, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 136. GLOBAL CONTRACEPTIVE PILLS MARKET SIZE, BY RETAIL PHARMACY, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 137. GLOBAL CONTRACEPTIVE PILLS MARKET SIZE, BY RETAIL PHARMACY, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 138. GLOBAL CONTRACEPTIVE PILLS MARKET SIZE, BY RETAIL PHARMACY, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 139. GLOBAL CONTRACEPTIVE PILLS MARKET SIZE, BY RETAIL PHARMACY, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 140. GLOBAL CONTRACEPTIVE PILLS MARKET SIZE, BY RETAIL PHARMACY, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 141. GLOBAL CONTRACEPTIVE PILLS MARKET SIZE, BY CHAIN PHARMACY, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 142. GLOBAL CONTRACEPTIVE PILLS MARKET SIZE, BY CHAIN PHARMACY, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 143. GLOBAL CONTRACEPTIVE PILLS MARKET SIZE, BY CHAIN PHARMACY, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 144. GLOBAL CONTRACEPTIVE PILLS MARKET SIZE, BY CHAIN PHARMACY, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 145. GLOBAL CONTRACEPTIVE PILLS MARKET SIZE, BY CHAIN PHARMACY, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 146. GLOBAL CONTRACEPTIVE PILLS MARKET SIZE, BY CHAIN PHARMACY, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 147. GLOBAL CONTRACEPTIVE PILLS MARKET SIZE, BY INDEPENDENT PHARMACY, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 148. GLOBAL CONTRACEPTIVE PILLS MARKET SIZE, BY INDEPENDENT PHARMACY, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 149. GLOBAL CONTRACEPTIVE PILLS MARKET SIZE, BY INDEPENDENT PHARMACY, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 150. GLOBAL CONTRACEPTIVE PILLS MARKET SIZE, BY INDEPENDENT PHARMACY, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 151. GLOBAL CONTRACEPTIVE PILLS MARKET SIZE, BY INDEPENDENT PHARMACY, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 152. GLOBAL CONTRACEPTIVE PILLS MARKET SIZE, BY INDEPENDENT PHARMACY, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 153. GLOBAL CONTRACEPTIVE PILLS MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 154. GLOBAL CONTRACEPTIVE PILLS MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 155. GLOBAL CONTRACEPTIVE PILLS MARKET SIZE, BY ADOLESCENTS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 156. GLOBAL CONTRACEPTIVE PILLS MARKET SIZE, BY ADOLESCENTS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 157. GLOBAL CONTRACEPTIVE PILLS MARKET SIZE, BY ADOLESCENTS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 158. GLOBAL CONTRACEPTIVE PILLS MARKET SIZE, BY ADOLESCENTS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 159. GLOBAL CONTRACEPTIVE PILLS MARKET SIZE, BY ADOLESCENTS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 160. GLOBAL CONTRACEPTIVE PILLS MARKET SIZE, BY ADOLESCENTS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 161. GLOBAL CONTRACEPTIVE PILLS MARKET SIZE, BY ADULTS, 2018-2024 (USD MILLION)
  • TABLE 162. GLOBAL CONTRACEPTIVE PILLS MARKET SIZE, BY ADULTS, 2025-2032 (USD MILLION)
  • TABLE 163. GLOBAL CONTRACEPTIVE PILLS MARKET SIZE, BY ADULTS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 164. GLOBAL CONTRACEPTIVE PILLS MARKET SIZE, BY ADULTS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 165. GLOBAL CONTRACEPTIVE PILLS MARKET SIZE, BY ADULTS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 166. GLOBAL CONTRACEPTIVE PILLS MARKET SIZE, BY ADULTS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 167. GLOBAL CONTRACEPTIVE PILLS MARKET SIZE, BY ADULTS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 168. GLOBAL CONTRACEPTIVE PILLS MARKET SIZE, BY ADULTS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 169. GLOBAL CONTRACEPTIVE PILLS MARKET SIZE, BY 20-24, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 170. GLOBAL CONTRACEPTIVE PILLS MARKET SIZE, BY 20-24, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 171. GLOBAL CONTRACEPTIVE PILLS MARKET SIZE, BY 20-24, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 172. GLOBAL CONTRACEPTIVE PILLS MARKET SIZE, BY 20-24, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 173. GLOBAL CONTRACEPTIVE PILLS MARKET SIZE, BY 20-24, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 174. GLOBAL CONTRACEPTIVE PILLS MARKET SIZE, BY 20-24, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 175. GLOBAL CONTRACEPTIVE PILLS MARKET SIZE, BY 25-29, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 176. GLOBAL CONTRACEPTIVE PILLS MARKET SIZE, BY 25-29, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 177. GLOBAL CONTRACEPTIVE PILLS MARKET SIZE, BY 25-29, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 178. GLOBAL CONTRACEPTIVE PILLS MARKET SIZE, BY 25-29, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 179. GLOBAL CONTRACEPTIVE PILLS MARKET SIZE, BY 25-29, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 180. GLOBAL CONTRACEPTIVE PILLS MARKET SIZE, BY 25-29, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 181. GLOBAL CONTRACEPTIVE PILLS MARKET SIZE, BY 30-34, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 182. GLOBAL CONTRACEPTIVE PILLS MARKET SIZE, BY 30-34, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 183. GLOBAL CONTRACEPTIVE PILLS MARKET SIZE, BY 30-34, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 184. GLOBAL CONTRACEPTIVE PILLS MARKET SIZE, BY 30-34, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 185. GLOBAL CONTRACEPTIVE PILLS MARKET SIZE, BY 30-34, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 186. GLOBAL CONTRACEPTIVE PILLS MARKET SIZE, BY 30-34, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 187. GLOBAL CONTRACEPTIVE PILLS MARKET SIZE, BY MATURE ADULTS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 188. GLOBAL CONTRACEPTIVE PILLS MARKET SIZE, BY MATURE ADULTS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 189. GLOBAL CONTRACEPTIVE PILLS MARKET SIZE, BY MATURE ADULTS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 190. GLOBAL CONTRACEPTIVE PILLS MARKET SIZE, BY MATURE ADULTS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 191. GLOBAL CONTRACEPTIVE PILLS MARKET SIZE, BY MATURE ADULTS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 192. GLOBAL CONTRACEPTIVE PILLS MARKET SIZE, BY MATURE ADULTS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 193. GLOBAL CONTRACEPTIVE PILLS MARKET SIZE, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 194. GLOBAL CONTRACEPTIVE PILLS MARKET SIZE, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 195. AMERICAS CONTRACEPTIVE PILLS MARKET SIZE, BY SUBREGION, 2018-2024 (USD MILLION)
  • TABLE 196. AMERICAS CONTRACEPTIVE PILLS MARKET SIZE, BY SUBREGION, 2025-2032 (USD MILLION)
  • TABLE 197. AMERICAS CONTRACEPTIVE PILLS MARKET SIZE, BY FORMULATION, 2018-2024 (USD MILLION)
  • TABLE 198. AMERICAS CONTRACEPTIVE PILLS MARKET SIZE, BY FORMULATION, 2025-2032 (USD MILLION)
  • TABLE 199. AMERICAS CONTRACEPTIVE PILLS MARKET SIZE, BY COMBINATION PILL, 2018-2024 (USD MILLION)
  • TABLE 200. AMERICAS CONTRACEPTIVE PILLS MARKET SIZE, BY COMBINATION PILL, 2025-2032 (USD MILLION)
  • TABLE 201. AMERICAS CONTRACEPTIVE PILLS MARKET SIZE, BY MONOPHASIC, 2018-2024 (USD MILLION)
  • TABLE 202. AMERICAS CONTRACEPTIVE PILLS MARKET SIZE, BY MONOPHASIC, 2025-2032 (USD MILLION)
  • TABLE 203. AMERICAS CONTRACEPTIVE PILLS MARKET SIZE, BY PACKAGING, 2018-2024 (USD MILLION)
  • TABLE 204. AMERICAS CONTRACEPTIVE PILLS MARKET SIZE, BY PACKAGING, 2025-2032 (USD MILLION)
  • TABLE 205. AMERICAS CONTRACEPTIVE PILLS MARKET SIZE, BY DOSAGE CYCLE, 2018-2024 (USD MILLION)
  • TABLE 206. AMERICAS CONTRACEPTIVE PILLS MARKET SIZE, BY DOSAGE CYCLE, 2025-2032 (USD MILLION)
  • TABLE 207. AMERICAS CONTRACEPTIVE PILLS MARKET SIZE, BY PRICING TIER, 2018-2024 (USD MILLION)
  • TABLE 208. AMERICAS CONTRACEPTIVE PILLS MARKET SIZE, BY PRICING TIER, 2025-2032 (USD MILLION)
  • TABLE 209. AMERICAS CONTRACEPTIVE PILLS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
  • TABLE 210. AMERICAS CONTRACEPTIVE PILLS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2032 (USD MILLION)
  • TABLE 211. AMERICAS CONTRACEPTIVE PILLS MARKET SIZE, BY RETAIL PHARMACY, 2018-2024 (USD MILLION)
  • TABLE 212. AMERICAS CONTRACEPTIVE PILLS MARKET SIZE, BY RETAIL PHARMACY, 2025-2032 (USD MILLION)
  • TABLE 213. AMERICAS CONTRACEPTIVE PILLS MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 214. AMERICAS CONTRACEPTIVE PILLS MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 215. AMERICAS CONTRACEPTIVE PILLS MARKET SIZE, BY ADULTS, 2018-2024 (USD MILLION)
  • TABLE 216. AMERICAS CONTRACEPTIVE PILLS MARKET SIZE, BY ADULTS, 2025-2032 (USD MILLION)
  • TABLE 217. NORTH AMERICA CONTRACEPTIVE PILLS MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 218. NORTH AMERICA CONTRACEPTIVE PILLS MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 219. NORTH AMERICA CONTRACEPTIVE PILLS MARKET SIZE, BY FORMULATION, 2018-2024 (USD MILLION)
  • TABLE 220. NORTH AMERICA CONTRACEPTIVE PILLS MARKET SIZE, BY FORMULATION, 2025-2032 (USD MILLION)
  • TABLE 221. NORTH AMERICA CONTRACEPTIVE PILLS MARKET SIZE, BY COMBINATION PILL, 2018-2024 (USD MILLION)
  • TABLE 222. NORTH AMERICA CONTRACEPTIVE PILLS MARKET SIZE, BY COMBINATION PILL, 2025-2032 (USD MILLION)
  • TABLE 223. NORTH AMERICA CONTRACEPTIVE PILLS MARKET SIZE, BY MONOPHASIC, 2018-2024 (USD MILLION)
  • TABLE 224. NORTH AMERICA CONTRACEPTIVE PILLS MARKET SIZE, BY MONOPHASIC, 2025-2032 (USD MILLION)
  • TABLE 225. NORTH AMERICA CONTRACEPTIVE PILLS MARKET SIZE, BY PACKAGING, 2018-2024 (USD MILLION)
  • TABLE 226. NORTH AMERICA CONTRACEPTIVE PILLS MARKET SIZE, BY PACKAGING, 2025-2032 (USD MILLION)
  • TABLE 227. NORTH AMERICA CONTRACEPTIVE PILLS MARKET SIZE, BY DOSAGE CYCLE, 2018-2024 (USD MILLION)
  • TABLE 228. NORTH AMERICA CONTRACEPTIVE PILLS MARKET SIZE, BY DOSAGE CYCLE, 2025-2032 (USD MILLION)
  • TABLE 229. NORTH AMERICA CONTRACEPTIVE PILLS MARKET SIZE, BY PRICING TIER, 2018-2024 (USD MILLION)
  • TABLE 230. NORTH AMERICA CONTRACEPTIVE PILLS MARKET SIZE, BY PRICING TIER, 2025-2032 (USD MILLION)
  • TABLE 231. NORTH AMERICA CONTRACEPTIVE PILLS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
  • TABLE 232. NORTH AMERICA CONTRACEPTIVE PILLS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2032 (USD MILLION)
  • TABLE 233. NORTH AMERICA CONTRACEPTIVE PILLS MARKET SIZE, BY RETAIL PHARMACY, 2018-2024 (USD MILLION)
  • TABLE 234. NORTH AMERICA CONTRACEPTIVE PILLS MARKET SIZE, BY RETAIL PHARMACY, 2025-2032 (USD MILLION)
  • TABLE 235. NORTH AMERICA CONTRACEPTIVE PILLS MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 236. NORTH AMERICA CONTRACEPTIVE PILLS MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 237. NORTH AMERICA CONTRACEPTIVE PILLS MARKET SIZE, BY ADULTS, 2018-2024 (USD MILLION)
  • TABLE 238. NORTH AMERICA CONTRACEPTIVE PILLS MARKET SIZE, BY ADULTS, 2025-2032 (USD MILLION)
  • TABLE 239. LATIN AMERICA CONTRACEPTIVE PILLS MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 240. LATIN AMERICA CONTRACEPTIVE PILLS MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 241. LATIN AMERICA CONTRACEPTIVE PILLS MARKET SIZE, BY FORMULATION, 2018-2024 (USD MILLION)
  • TABLE 242. LATIN AMERICA CONTRACEPTIVE PILLS MARKET SIZE, BY FORMULATION, 2025-2032 (USD MILLION)
  • TABLE 243. LATIN AMERICA CONTRACEPTIVE PILLS MARKET SIZE, BY COMBINATION PILL, 2018-2024 (USD MILLION)
  • TABLE 244. LATIN AMERICA CONTRACEPTIVE PILLS MARKET SIZE, BY COMBINATION PILL, 2025-2032 (USD MILLION)
  • TABLE 245. LATIN AMERICA CONTRACEPTIVE PILLS MARKET SIZE, BY MONOPHASIC, 2018-2024 (USD MILLION)
  • TABLE 246. LATIN AMERICA CONTRACEPTIVE PILLS MARKET SIZE, BY MONOPHASIC, 2025-2032 (USD MILLION)
  • TABLE 247. LATIN AMERICA CONTRACEPTIVE PILLS MARKET SIZE, BY PACKAGING, 2018-2024 (USD MILLION)
  • TABLE 248. LATIN AMERICA CONTRACEPTIVE PILLS MARKET SIZE, BY PACKAGING, 2025-2032 (USD MILLION)
  • TABLE 249. LATIN AMERICA CONTRACEPTIVE PILLS MARKET SIZE, BY DOSAGE CYCLE, 2018-2024 (USD MILLION)
  • TABLE 250. LATIN AMERICA CONTRACEPTIVE PILLS MARKET SIZE, BY DOSAGE CYCLE, 2025-2032 (USD MILLION)
  • TABLE 251. LATIN AMERICA CONTRACEPTIVE PILLS MARKET SIZE, BY PRICING TIER, 2018-2024 (USD MILLION)
  • TABLE 252. LATIN AMERICA CONTRACEPTIVE PILLS MARKET SIZE, BY PRICING TIER, 2025-2032 (USD MILLION)
  • TABLE 253. LATIN AMERICA CONTRACEPTIVE PILLS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
  • TABLE 254. LATIN AMERICA CONTRACEPTIVE PILLS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2032 (USD MILLION)
  • TABLE 255. LATIN AMERICA CONTRACEPTIVE PILLS MARKET SIZE, BY RETAIL PHARMACY, 2018-2024 (USD MILLION)
  • TABLE 256. LATIN AMERICA CONTRACEPTIVE PILLS MARKET SIZE, BY RETAIL PHARMACY, 2025-2032 (USD MILLION)
  • TABLE 257. LATIN AMERICA CONTRACEPTIVE PILLS MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 258. LATIN AMERICA CONTRACEPTIVE PILLS MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 259. LATIN AMERICA CONTRACEPTIVE PILLS MARKET SIZE, BY ADULTS, 2018-2024 (USD MILLION)
  • TABLE 260. LATIN AMERICA CONTRACEPTIVE PILLS MARKET SIZE, BY ADULTS, 2025-2032 (USD MILLION)
  • TABLE 261. EUROPE, MIDDLE EAST & AFRICA CONTRACEPTIVE PILLS MARKET SIZE, BY SUBREGION, 2018-2024 (USD MILLION)
  • TABLE 262. EUROPE, MIDDLE EAST & AFRICA CONTRACEPTIVE PILLS MARKET SIZE, BY SUBREGION, 2025-2032 (USD MILLION)
  • TABLE 263. EUROPE, MIDDLE EAST & AFRICA CONTRACEPTIVE PILLS MARKET SIZE, BY FORMULATION, 2018-2024 (USD MILLION)
  • TABLE 264. EUROPE, MIDDLE EAST & AFRICA CONTRACEPTIVE PILLS MARKET SIZE, BY FORMULATION, 2025-2032 (USD MILLION)
  • TABLE 265. EUROPE, MIDDLE EAST & AFRICA CONTRACEPTIVE PILLS MARKET SIZE, BY COMBINATION PILL, 2018-2024 (USD MILLION)
  • TABLE 266. EUROPE, MIDDLE EAST & AFRICA CONTRACEPTIVE PILLS MARKET SIZE, BY COMBINATION PILL, 2025-2032 (USD MILLION)
  • TABLE 267. EUROPE, MIDDLE EAST & AFRICA CONTRACEPTIVE PILLS MARKET SIZE, BY MONOPHASIC, 2018-2024 (USD MILLION)
  • TABLE 268. EUROPE, MIDDLE EAST & AFRICA CONTRACEPTIVE PILLS MARKET SIZE, BY MONOPHASIC, 2025-2032 (USD MILLION)
  • TABLE 269. EUROPE, MIDDLE EAST & AFRICA CONTRACEPTIVE PILLS MARKET SIZE, BY PACKAGING, 2018-2024 (USD MILLION)
  • TABLE 270. EUROPE, MIDDLE EAST & AFRICA CONTRACEPTIVE PILLS MARKET SIZE, BY PACKAGING, 2025-2032 (USD MILLION)
  • TABLE 271. EUROPE, MIDDLE EAST & AFRICA CONTRACEPTIVE PILLS MARKET SIZE, BY DOSAGE CYCLE, 2018-2024 (USD MILLION)
  • TABLE 272. EUROPE, MIDDLE EAST & AFRICA CONTRACEPTIVE PILLS MARKET SIZE, BY DOSAGE CYCLE, 2025-2032 (USD MILLION)
  • TABLE 273. EUROPE, MIDDLE EAST & AFRICA CONTRACEPTIVE PILLS MARKET SIZE, BY PRICING TIER, 2018-2024 (USD MILLION)
  • TABLE 274. EUROPE, MIDDLE EAST & AFRICA CONTRACEPTIVE PILLS MARKET SIZE, BY PRICING TIER, 2025-2032 (USD MILLION)
  • TABLE 275. EUROPE, MIDDLE EAST & AFRICA CONTRACEPTIVE PILLS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
  • TABLE 276. EUROPE, MIDDLE EAST & AFRICA CONTRACEPTIVE PILLS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2032 (USD MILLION)
  • TABLE 277. EUROPE, MIDDLE EAST & AFRICA CONTRACEPTIVE PILLS MARKET SIZE, BY RETAIL PHARMACY, 2018-2024 (USD MILLION)
  • TABLE 278. EUROPE, MIDDLE EAST & AFRICA CONTRACEPTIVE PILLS MARKET SIZE, BY RETAIL PHARMACY, 2025-2032 (USD MILLION)
  • TABLE 279. EUROPE, MIDDLE EAST & AFRICA CONTRACEPTIVE PILLS MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 280. EUROPE, MIDDLE EAST & AFRICA CONTRACEPTIVE PILLS MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 281. EUROPE, MIDDLE EAST & AFRICA CONTRACEPTIVE PILLS MARKET SIZE, BY ADULTS, 2018-2024 (USD MILLION)
  • TABLE 282. EUROPE, MIDDLE EAST & AFRICA CONTRACEPTIVE PILLS MARKET SIZE, BY ADULTS, 2025-2032 (USD MILLION)
  • TABLE 283. EUROPE CONTRACEPTIVE PILLS MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 284. EUROPE CONTRACEPTIVE PILLS MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 285. EUROPE CONTRACEPTIVE PILLS MARKET SIZE, BY FORMULATION, 2018-2024 (USD MILLION)
  • TABLE 286. EUROPE CONTRACEPTIVE PILLS MARKET SIZE, BY FORMULATION, 2025-2032 (USD MILLION)
  • TABLE 287. EUROPE CONTRACEPTIVE PILLS MARKET SIZE, BY COMBINATION PILL, 2018-2024 (USD MILLION)
  • TABLE 288. EUROPE CONTRACEPTIVE PILLS MARKET SIZE, BY COMBINATION PILL, 2025-2032 (USD MILLION)
  • TABLE 289. EUROPE CONTRACEPTIVE PILLS MARKET SIZE, BY MONOPHASIC, 2018-2024 (USD MILLION)
  • TABLE 290. EUROPE CONTRACEPTIVE PILLS MARKET SIZE, BY MONOPHASIC, 2025-2032 (USD MILLION)
  • TABLE 291. EUROPE CONTRACEPTIVE PILLS MARKET SIZE, BY PACKAGING, 2018-2024 (USD MILLION)
  • TABLE 292. EUROPE CONTRACEPTIVE PILLS MARKET SIZE, BY PACKAGING, 2025-2032 (USD MILLION)
  • TABLE 293. EUROPE CONTRACEPTIVE PILLS MARKET SIZE, BY DOSAGE CYCLE, 2018-2024 (USD MILLION)
  • TABLE 294. EUROPE CONTRACEPTIVE PILLS MARKET SIZE, BY DOSAGE CYCLE, 2025-2032 (USD MILLION)
  • TABLE 295. EUROPE CONTRACEPTIVE PILLS MARKET SIZE, BY PRICING TIER, 2018-2024 (USD MILLION)
  • TABLE 296. EUROPE CONTRACEPTIVE PILLS MARKET SIZE, BY PRICING TIER, 2025-2032 (USD MILLION)
  • TABLE 297. EUROPE CONTRACEPTIVE PILLS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
  • TABLE 298. EUROPE CONTRACEPTIVE PILLS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2032 (USD MILLION)
  • TABLE 299. EUROPE CONTRACEPTIVE PILLS MARKET SIZE, BY RETAIL PHARMACY, 2018-2024 (USD MILLION)
  • TABLE 300. EUROPE CONTRACEPTIVE PILLS MARKET SIZE, BY RETAIL PHARMACY, 2025-2032 (USD MILLION)
  • TABLE 301. EUROPE CONTRACEPTIVE PILLS MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 302. EUROPE CONTRACEPTIVE PILLS MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 303. EUROPE CONTRACEPTIVE PILLS MARKET SIZE, BY ADULTS, 2018-2024 (USD MILLION)
  • TABLE 304. EUROPE CONTRACEPTIVE PILLS MARKET SIZE, BY ADULTS, 2025-2032 (USD MILLION)
  • TABLE 305. MIDDLE EAST CONTRACEPTIVE PILLS MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 306. MIDDLE EAST CONTRACEPTIVE PILLS MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 307. MIDDLE EAST CONTRACEPTIVE PILLS MARKET SIZE, BY FORMULATION, 2018-2024 (USD MILLION)
  • TABLE 308. MIDDLE EAST CONTRACEPTIVE PILLS MARKET SIZE, BY FORMULATION, 2025-2032 (USD MILLION)
  • TABLE 309. MIDDLE EAST CONTRACEPTIVE PILLS MARKET SIZE, BY COMBINATION PILL, 2018-2024 (USD MILLION)
  • TABLE 310. MIDDLE EAST CONTRACEPTIVE PILLS MARKET SIZE, BY COMBINATION PILL, 2025-2032 (USD MILLION)
  • TABLE 311. MIDDLE EAST CONTRACEPTIVE PILLS MARKET SIZE, BY MONOPHASIC, 2018-2024 (USD MILLION)
  • TABLE 312. MIDDLE EAST CONTRACEPTIVE PILLS MARKET SIZE, BY MONOPHASIC, 2025-2032 (USD MILLION)
  • TABLE 313. MIDDLE EAST CONTRACEPTIVE PILLS MARKET SIZE, BY PACKAGING, 2018-2024 (USD MILLION)
  • TABLE 314. MIDDLE EAST CONTRACEPTIVE PILLS MARKET SIZE, BY PACKAGING, 2025-2032 (USD MILLION)
  • TABLE 315. MIDDLE EAST CONTRACEPTIVE PILLS MARKET SIZE, BY DOSAGE CYCLE, 2018-2024 (USD MILLION)
  • TABLE 316. MIDDLE EAST CONTRACEPTIVE PILLS MARKET SIZE, BY DOSAGE CYCLE, 2025-2032 (USD MILLION)
  • TABLE 317. MIDDLE EAST CONTRACEPTIVE PILLS MARKET SIZE, BY PRICING TIER, 2018-2024 (USD MILLION)
  • TABLE 318. MIDDLE EAST CONTRACEPTIVE PILLS MARKET SIZE, BY PRICING TIER, 2025-2032 (USD MILLION)
  • TABLE 319. MIDDLE EAST CONTRACEPTIVE PILLS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
  • TABLE 320. MIDDLE EAST CONTRACEPTIVE PILLS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2032 (USD MILLION)
  • TABLE 321. MIDDLE EAST CONTRACEPTIVE PILLS MARKET SIZE, BY RETAIL PHARMACY, 2018-2024 (USD MILLION)
  • TABLE 322. MIDDLE EAST CONTRACEPTIVE PILLS MARKET SIZE, BY RETAIL PHARMACY, 2025-2032 (USD MILLION)
  • TABLE 323. MIDDLE EAST CONTRACEPTIVE PILLS MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 324. MIDDLE EAST CONTRACEPTIVE PILLS MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 325. MIDDLE EAST CONTRACEPTIVE PILLS MARKET SIZE, BY ADULTS, 2018-2024 (USD MILLION)
  • TABLE 326. MIDDLE EAST CONTRACEPTIVE PILLS MARKET SIZE, BY ADULTS, 2025-2032 (USD MILLION)
  • TABLE 327. AFRICA CONTRACEPTIVE PILLS MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 328. AFRICA CONTRACEPTIVE PILLS MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 329. AFRICA CONTRACEPTIVE PILLS MARKET SIZE, BY FORMULATION, 2018-2024 (USD MILLION)
  • TABLE 330. AFRICA CONTRACEPTIVE PILLS MARKET SI